APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vigabatrin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vigabatrin Market Outlook and Growth Opportunities 2026

20 December 2025198 pages

Choose your research edition.

Industry ResearchVigabatrin Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Vigabatrin Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Vigabatrin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vigabatrin Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Vigabatrin Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Vigabatrin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vigabatrin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vigabatrin market include Sanofi, Novartis, Upsher-Smith, Perrigo, Lundbeck, Grindeks, Endo International, Dr. Fisher Farma and Cipla, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vigabatrin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vigabatrin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vigabatrin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vigabatrin market size, projected growth trends, production technologies, key applications, and end-use industries.

Vigabatrin Segment by Company

Sanofi

Novartis

Upsher-Smith

Perrigo

Lundbeck

Grindeks

Endo International

Dr. Fisher Farma

Cipla

Benta Pharma Industries

Amneal Pharma

Vigabatrin Segment by Type

Tablet

Powder

Vigabatrin Segment by Application

Partial-Onset Seizures

Refractory Complex Partial Seizures

Infantile Spasms (IS)

Vigabatrin Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Vigabatrin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vigabatrin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vigabatrin significant trends, drivers, influence factors in global and regions.

6. To analyze Vigabatrin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vigabatrin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vigabatrin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vigabatrin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vigabatrin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vigabatrin industry.

Chapter 3: Detailed analysis of Vigabatrin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vigabatrin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vigabatrin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vigabatrin Industry Trends Table 2. Vigabatrin Industry Drivers Table 3. Vigabatrin Industry Opportunities and Challenges Table 4. Vigabatrin Industry Restraints Table 5. Global Vigabatrin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vigabatrin Revenue Share by Company (2021-2026) Table 7. Global Vigabatrin Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Vigabatrin Sales Volume Share by Company (2021-2026) Table 9. Global Vigabatrin Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Vigabatrin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vigabatrin Key Company Manufacturing Base & Headquarters Table 12. Global Vigabatrin Company, Product Type & Application Table 13. Global Vigabatrin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vigabatrin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tablet Table 18. Significant Companies of Powder Table 19. Global Vigabatrin Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Vigabatrin Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Vigabatrin Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Vigabatrin Sales Volume Share by Type (2021-2026) Table 23. Global Vigabatrin Sales Volume Share by Type (2027-2032) Table 24. Global Vigabatrin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Vigabatrin Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Vigabatrin Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Vigabatrin Sales Value Share by Type (2021-2026) Table 28. Global Vigabatrin Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Partial-Onset Seizures Table 30. Significant Companies of Refractory Complex Partial Seizures Table 31. Significant Companies of Infantile Spasms (IS) Table 32. Global Vigabatrin Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Vigabatrin Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Vigabatrin Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Vigabatrin Sales Volume Share by Application (2021-2026) Table 36. Global Vigabatrin Sales Volume Share by Application (2027-2032) Table 37. Global Vigabatrin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Vigabatrin Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Vigabatrin Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Vigabatrin Sales Value Share by Application (2021-2026) Table 41. Global Vigabatrin Sales Value Share by Application (2027-2032) Table 42. Global Vigabatrin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Vigabatrin Sales by Region (2021-2026) & (K Units) Table 44. Global Vigabatrin Sales Market Share by Region (2021-2026) Table 45. Global Vigabatrin Sales by Region (2027-2032) & (K Units) Table 46. Global Vigabatrin Sales Market Share by Region (2027-2032) Table 47. Global Vigabatrin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Vigabatrin Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Vigabatrin Sales Value Share by Region (2021-2026) Table 50. Global Vigabatrin Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Vigabatrin Sales Value Share by Region (2027-2032) Table 52. Global Vigabatrin Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Vigabatrin Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Vigabatrin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Vigabatrin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Vigabatrin Sales by Country (2021-2026) & (K Units) Table 57. Global Vigabatrin Sales Market Share by Country (2021-2026) Table 58. Global Vigabatrin Sales by Country (2027-2032) & (K Units) Table 59. Global Vigabatrin Sales Market Share by Country (2027-2032) Table 60. Global Vigabatrin Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Vigabatrin Sales Value Market Share by Country (2021-2026) Table 62. Global Vigabatrin Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Vigabatrin Sales Value Market Share by Country (2027-2032) Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Sanofi Vigabatrin Product Portfolio Table 68. Sanofi Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novartis Vigabatrin Product Portfolio Table 73. Novartis Recent Development Table 74. Upsher-Smith Company Information Table 75. Upsher-Smith Business Overview Table 76. Upsher-Smith Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Upsher-Smith Vigabatrin Product Portfolio Table 78. Upsher-Smith Recent Development Table 79. Perrigo Company Information Table 80. Perrigo Business Overview Table 81. Perrigo Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Perrigo Vigabatrin Product Portfolio Table 83. Perrigo Recent Development Table 84. Lundbeck Company Information Table 85. Lundbeck Business Overview Table 86. Lundbeck Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Lundbeck Vigabatrin Product Portfolio Table 88. Lundbeck Recent Development Table 89. Grindeks Company Information Table 90. Grindeks Business Overview Table 91. Grindeks Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Grindeks Vigabatrin Product Portfolio Table 93. Grindeks Recent Development Table 94. Endo International Company Information Table 95. Endo International Business Overview Table 96. Endo International Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Endo International Vigabatrin Product Portfolio Table 98. Endo International Recent Development Table 99. Dr. Fisher Farma Company Information Table 100. Dr. Fisher Farma Business Overview Table 101. Dr. Fisher Farma Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Dr. Fisher Farma Vigabatrin Product Portfolio Table 103. Dr. Fisher Farma Recent Development Table 104. Cipla Company Information Table 105. Cipla Business Overview Table 106. Cipla Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Cipla Vigabatrin Product Portfolio Table 108. Cipla Recent Development Table 109. Benta Pharma Industries Company Information Table 110. Benta Pharma Industries Business Overview Table 111. Benta Pharma Industries Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Benta Pharma Industries Vigabatrin Product Portfolio Table 113. Benta Pharma Industries Recent Development Table 114. Amneal Pharma Company Information Table 115. Amneal Pharma Business Overview Table 116. Amneal Pharma Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Amneal Pharma Vigabatrin Product Portfolio Table 118. Amneal Pharma Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Vigabatrin Distributors List Table 122. Vigabatrin Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Vigabatrin Product Image Figure 2. Global Vigabatrin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vigabatrin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vigabatrin Sales (2021-2032) & (K Units) Figure 5. Global Vigabatrin Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Vigabatrin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tablet Image Figure 10. Powder Image Figure 11. Global Vigabatrin Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Vigabatrin Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Vigabatrin Sales Volume Share by Type (2021-2032) Figure 14. Global Vigabatrin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Vigabatrin Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Vigabatrin Sales Value Share by Type (2021-2032) Figure 17. Partial-Onset Seizures Image Figure 18. Refractory Complex Partial Seizures Image Figure 19. Infantile Spasms (IS) Image Figure 20. Global Vigabatrin Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Vigabatrin Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Vigabatrin Sales Volume Share by Application (2021-2032) Figure 23. Global Vigabatrin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Vigabatrin Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Vigabatrin Sales Value Share by Application (2021-2032) Figure 26. Global Vigabatrin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Vigabatrin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Vigabatrin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Vigabatrin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Vigabatrin Sales Value (2021-2032) & (US$ Million) Figure 31. North America Vigabatrin Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Vigabatrin Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Vigabatrin Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Vigabatrin Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Vigabatrin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Vigabatrin Sales Value (2021-2032) & (US$ Million) Figure 37. South America Vigabatrin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Vigabatrin Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Vigabatrin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Vigabatrin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Vigabatrin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Vigabatrin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Vigabatrin Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Vigabatrin Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Powder
Applications
  • Partial-Onset Seizures
  • Refractory Complex Partial Seizures
  • Infantile Spasms (IS)
Companies covered
  • Sanofi
  • Novartis
  • Upsher-Smith
  • Perrigo
  • Lundbeck
  • Grindeks
  • Endo International
  • Dr. Fisher Farma
  • Cipla
  • Benta Pharma Industries
  • Amneal Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vigabatrin Sales Value (2021-2032)
  4. 1.2.2 Global Vigabatrin Sales Volume (2021-2032)
  5. 1.2.3 Global Vigabatrin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vigabatrin Market Dynamics
  1. 2.1 Vigabatrin Industry Trends
  2. 2.2 Vigabatrin Industry Drivers
  3. 2.3 Vigabatrin Industry Opportunities and Challenges
  4. 2.4 Vigabatrin Industry Restraints
3 Vigabatrin Market by Company
  1. 3.1 Global Vigabatrin Company Revenue Ranking in 2025
  2. 3.2 Global Vigabatrin Revenue by Company (2021-2026)
  3. 3.3 Global Vigabatrin Sales Volume by Company (2021-2026)
  4. 3.4 Global Vigabatrin Average Price by Company (2021-2026)
  5. 3.5 Global Vigabatrin Company Ranking (2024-2026)
  6. 3.6 Global Vigabatrin Company Manufacturing Base and Headquarters
  7. 3.7 Global Vigabatrin Company Product Type and Application
  8. 3.8 Global Vigabatrin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vigabatrin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vigabatrin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vigabatrin Market by Type
  1. 4.1 Vigabatrin Type Introduction
  2. 4.1.1 Tablet
  3. 4.1.2 Powder
  4. 4.2 Global Vigabatrin Sales Volume by Type
  5. 4.2.1 Global Vigabatrin Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vigabatrin Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Vigabatrin Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Vigabatrin Sales Value by Type
  9. 4.3.1 Global Vigabatrin Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Vigabatrin Sales Value by Type (2021-2032)
  11. 4.3.3 Global Vigabatrin Sales Value Share by Type (2021-2032)
5 Vigabatrin Market by Application
  1. 5.1 Vigabatrin Application Introduction
  2. 5.1.1 Partial-Onset Seizures
  3. 5.1.2 Refractory Complex Partial Seizures
  4. 5.1.3 Infantile Spasms (IS)
  5. 5.2 Global Vigabatrin Sales Volume by Application
  6. 5.2.1 Global Vigabatrin Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vigabatrin Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Vigabatrin Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Vigabatrin Sales Value by Application
  10. 5.3.1 Global Vigabatrin Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Vigabatrin Sales Value by Application (2021-2032)
  12. 5.3.3 Global Vigabatrin Sales Value Share by Application (2021-2032)
6 Vigabatrin Regional Sales and Value Analysis
  1. 6.1 Global Vigabatrin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vigabatrin Sales by Region (2021-2032)
  3. 6.2.1 Global Vigabatrin Sales by Region: 2021-2026
  4. 6.2.2 Global Vigabatrin Sales by Region (2027-2032)
  5. 6.3 Global Vigabatrin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vigabatrin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vigabatrin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vigabatrin Sales Value by Region (2027-2032)
  9. 6.5 Global Vigabatrin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vigabatrin Sales Value (2021-2032)
  12. 6.6.2 North America Vigabatrin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vigabatrin Sales Value (2021-2032)
  15. 6.7.2 Europe Vigabatrin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vigabatrin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vigabatrin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vigabatrin Sales Value (2021-2032)
  21. 6.9.2 South America Vigabatrin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vigabatrin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vigabatrin Sales Value Share by Country, 2025 VS 2032
7 Vigabatrin Country-level Sales and Value Analysis
  1. 7.1 Global Vigabatrin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vigabatrin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vigabatrin Sales by Country (2021-2032)
  4. 7.3.1 Global Vigabatrin Sales by Country (2021-2026)
  5. 7.3.2 Global Vigabatrin Sales by Country (2027-2032)
  6. 7.4 Global Vigabatrin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vigabatrin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vigabatrin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vigabatrin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vigabatrin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vigabatrin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vigabatrin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vigabatrin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vigabatrin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vigabatrin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vigabatrin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vigabatrin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vigabatrin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vigabatrin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vigabatrin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vigabatrin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vigabatrin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vigabatrin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vigabatrin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vigabatrin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vigabatrin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vigabatrin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vigabatrin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vigabatrin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vigabatrin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vigabatrin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vigabatrin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vigabatrin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vigabatrin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vigabatrin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vigabatrin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vigabatrin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vigabatrin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vigabatrin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vigabatrin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vigabatrin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vigabatrin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vigabatrin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vigabatrin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vigabatrin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vigabatrin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vigabatrin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vigabatrin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vigabatrin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vigabatrin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vigabatrin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vigabatrin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vigabatrin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vigabatrin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vigabatrin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vigabatrin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vigabatrin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vigabatrin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vigabatrin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vigabatrin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vigabatrin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vigabatrin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vigabatrin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vigabatrin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vigabatrin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vigabatrin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vigabatrin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vigabatrin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vigabatrin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vigabatrin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vigabatrin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vigabatrin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vigabatrin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vigabatrin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vigabatrin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vigabatrin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vigabatrin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vigabatrin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vigabatrin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vigabatrin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vigabatrin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vigabatrin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vigabatrin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vigabatrin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vigabatrin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vigabatrin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vigabatrin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vigabatrin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vigabatrin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vigabatrin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vigabatrin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vigabatrin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Vigabatrin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Vigabatrin Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Vigabatrin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Vigabatrin Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Upsher-Smith
  14. 8.3.1 Upsher-Smith Company Information
  15. 8.3.2 Upsher-Smith Business Overview
  16. 8.3.3 Upsher-Smith Vigabatrin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Upsher-Smith Vigabatrin Product Portfolio
  18. 8.3.5 Upsher-Smith Recent Developments
  19. 8.4 Perrigo
  20. 8.4.1 Perrigo Company Information
  21. 8.4.2 Perrigo Business Overview
  22. 8.4.3 Perrigo Vigabatrin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Perrigo Vigabatrin Product Portfolio
  24. 8.4.5 Perrigo Recent Developments
  25. 8.5 Lundbeck
  26. 8.5.1 Lundbeck Company Information
  27. 8.5.2 Lundbeck Business Overview
  28. 8.5.3 Lundbeck Vigabatrin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lundbeck Vigabatrin Product Portfolio
  30. 8.5.5 Lundbeck Recent Developments
  31. 8.6 Grindeks
  32. 8.6.1 Grindeks Company Information
  33. 8.6.2 Grindeks Business Overview
  34. 8.6.3 Grindeks Vigabatrin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Grindeks Vigabatrin Product Portfolio
  36. 8.6.5 Grindeks Recent Developments
  37. 8.7 Endo International
  38. 8.7.1 Endo International Company Information
  39. 8.7.2 Endo International Business Overview
  40. 8.7.3 Endo International Vigabatrin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Endo International Vigabatrin Product Portfolio
  42. 8.7.5 Endo International Recent Developments
  43. 8.8 Dr. Fisher Farma
  44. 8.8.1 Dr. Fisher Farma Company Information
  45. 8.8.2 Dr. Fisher Farma Business Overview
  46. 8.8.3 Dr. Fisher Farma Vigabatrin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Dr. Fisher Farma Vigabatrin Product Portfolio
  48. 8.8.5 Dr. Fisher Farma Recent Developments
  49. 8.9 Cipla
  50. 8.9.1 Cipla Company Information
  51. 8.9.2 Cipla Business Overview
  52. 8.9.3 Cipla Vigabatrin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Cipla Vigabatrin Product Portfolio
  54. 8.9.5 Cipla Recent Developments
  55. 8.10 Benta Pharma Industries
  56. 8.10.1 Benta Pharma Industries Company Information
  57. 8.10.2 Benta Pharma Industries Business Overview
  58. 8.10.3 Benta Pharma Industries Vigabatrin Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Benta Pharma Industries Vigabatrin Product Portfolio
  60. 8.10.5 Benta Pharma Industries Recent Developments
  61. 8.11 Amneal Pharma
  62. 8.11.1 Amneal Pharma Company Information
  63. 8.11.2 Amneal Pharma Business Overview
  64. 8.11.3 Amneal Pharma Vigabatrin Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Amneal Pharma Vigabatrin Product Portfolio
  66. 8.11.5 Amneal Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vigabatrin Value Chain Analysis
  2. 9.1.1 Vigabatrin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vigabatrin Sales Mode & Process
  6. 9.2 Vigabatrin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vigabatrin Distributors
  9. 9.2.3 Vigabatrin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst